DyoDelta Biosciences in association with Sachs
Associates presented the 2007 Life Science
Innovation Awards at the European Life Science CEO Forum for
Investing & Partnering in Biotech, Medtech, Speciality
Pharma & Emerging Markets , held in Zurich in April 2008.
The event focused on growth companies and new business
champions in the sector with participation from industry
leaders. The forum featured discussion panels, biotech
company presentation and partnering presentations headed by
senior Big Pharma representatives, highlighting current and
future strategic trends.
Our panel of expert judges from the pharma
industry and the financial world that voted for the awards
included:
Dr Regina Hodits, Partner, Atlas Venture
Harry Loveys, Principal, Capital Royalty
LLC
Dimitri Dimitriou, Managing Partner,
DyoDelta Biosciences
Jose Maria Romero, Vice President
Transactions, Worldwide Business Development,
GlaxoSmithKline
Dr Margaret Beer, Director, Scientific
Liaison, Licensing and External Research, Europe, Merck,
Sharp & Dohme
Dr Peter Johann, General Partner, NGN
Capital
Dr Alex Chanas, Senior Director, Worldwide
Licensing and Business Development, Pfizer Inc.
Sandrine Cailleteau, CBO, Plethora
Solutions
Laurent Feniou, Managing Director
Healthcare, Rothschild
Deborah Harland, Partner, SR One
Andrew Weiss, Vice President,
Biotechnology/Pharmaceutical Analyst, Bank Vontobel AG
|
■
2007 Partnering Deal of the Year Award
The winner of the Partnering deal of the Year
for 2007 was Morphosys with its deal with Novartis -
one of the largest ever R&D deals. $600m COMMITTED
payments; total potential over $1bn (plus
royalties). The nominees were: Ablynx, Morphosys,
Antisoma and Oxford Biomedica.
|
 ■
2007 Financing of the Year Award
The winner of the Financing of the Year for 2007
was EUSA Pharma, with a $175m venture capital raised
from syndicate of investors, the largest ever
European pharmaceutical fund raise. The nominees
were: EUSA, Addex Pharmaceuticals and Noxxon.
|
 ■
2007 Investor of the Year Award
The winners of the Investor of the Year for 2007
were jointly Abingworth, having raised £300 million
($587 million) in 2007 - largest venture fund
dedicated to life sciences raised by a firm based in
Europe and GLSV being one of the youngest (10 years
old) European firms with a very good track record.
The nominees were: Abingworth, Atlas and GLSV. .
|
 ■
2007 Pharma "Partner of Choice"of the Year Award
The winner of the Pharma partner of choice of the
year for 2007 was GlaxoSmithKline. In 2007, GSK
executed 6 deals in late-stage clinical development
and 5 wide-scope external development
collaborations. GSK has been creative in putting
together new deal structures. More than 85% of the
products resulting from past in-licensing deals are
still in active development, and the vast majority
of them have progressed at least 1 or more
development stages, 11 are in the market. The
nominees were: GSK, Pfizer, Novartis and UCB .
|
|
